Compare Mesoblast Limited (MESO) vs Ermenegildo Zegna N.V. Ordinary Shares (ZGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Ermenegildo Zegna N.V. Ordinary Shares — how do they compare? Mesoblast Limited trades at $13.76 (market cap $1.80B), while Ermenegildo Zegna N.V. Ordinary Shares trades at $12.8 (market cap $3.44B). The key difference: Ermenegildo Zegna N.V. Ordinary Shares is the larger of the two by market cap, and Ermenegildo Zegna N.V. Ordinary Shares pays a 1.07% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and Ermenegildo Zegna N.V. Ordinary Shares for 0 Days on average.
| MESO | ZGN | |
|---|---|---|
Market Cap | $1.80B | $3.44B |
Volume | 225,551 | 781,107 |
Sector | Health | Consumer Cyclical |
52-Week High | $20.96 | $15.25 |
52-Week Low | $13.19 | $8.69 |
Typical Hold Time | 15 Days | 0 Days |
Enterprise Value | $1.88B | $4.40B |
Dividend Yield | — | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.895, down 2.63% with bearish technical signals. The company reported substantial revenue growth to $120M in 2026 but remains unprofitable with a net margin of -47.82%. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant milestones. The stock shows mixed sentiment with 45% analyst buy ratings against bearish technical indicators.
While MESO demonstrates strong revenue growth potential and pipeline progress, persistent losses and negative profitability metrics present substantial risk. The company's cash position of $161M provides runway, but investors face volatility from clinical trial outcomes and path to profitability challenges.
ZGN trades at $12.94, up 2.7% with a neutral technical outlook. The stock shows mixed fundamentals with a high P/E of 38.5 but strong gross margins of 67.58%. Recent earnings beat expectations in three of the last four quarters, though Q2 2026 missed estimates. Analyst consensus is bullish with a $14.12 price target and 66.7% buy ratings. Revenue growth continues with 2025 reaching $1.92B, though net margins compressed to 3.98%.
ZGN presents a growth opportunity with expanding DTC momentum and margin potential, but faces valuation concerns and competitive pressures. The stock's upside depends on sustained earnings growth and successful execution of the retail-first strategy amidst fashion sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Ermenegildo Zegna N.V. Ordinary Shares
Ermenegildo Zegna N.V. is a luxury fashion group whose brands include Zegna, Thom Browne, and Tom Ford Fashion. The company operates a vertically integrated supply chain, sourcing wool from its own Australian farm through to finished garment production.
Read more on ZGN →
